2invest AG (Frankfurt: 2INV; ISIN: DE000A3H3L44; Prime Standard) today published its quarterly statement as at 31 March 2021.
In the first quarter of 2021, the transformation into an investment company, the change of name from 4basebio AG to 2invest AG and the capital reduction in the ratio of 9:1 (nine old shares were merged into one new share) were completed. The focus of 2invest AG as an investment company is on strategic investments with a good opportunity/risk ratio, primarily in the biotechnology, life science and IT sectors. The interim reporting period Q1/2021 was closed with a net profit (HGB) of TEUR 88 and freely available liquid funds (consisting of cash and bank balances plus liquid securities) of EUR 63.7 million as of 31 March 2021. Book equity (HGB) increased to EUR 84.6 million as of 31 March 2021. Interested shareholders can find the complete quarterly statement on the company's homepage at https://2invest-ag.com/financial-reporting/.
The Management Board
For further information please contact:
Hansjörg Plaggemars, Board of Directors
Tel: +49 06221 649240
Ziegelhäuser Landstr. 3
|Contact Person:||Hansjörg Plaggemars|
|Phone:||+49 6221 649 240|
|Stock Exchange(s):||Regulated Market in Frankfurt; Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate|